Bellevue Group AG Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bellevue Group AG trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 770,268 shares of the biopharmaceutical company's stock after selling 38,827 shares during the quarter. Alnylam Pharmaceuticals comprises about 3.5% of Bellevue Group AG's holdings, making the stock its 11th largest position. Bellevue Group AG owned 0.60% of Alnylam Pharmaceuticals worth $181,252,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Regeneron Pharmaceuticals Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $1,045,822,000. Norges Bank purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $577,941,000. Capital Research Global Investors increased its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 496.6% during the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after acquiring an additional 315,182 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock worth $1,875,627 in the last quarter. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of research analyst reports. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Scotiabank upped their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 31st. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Finally, Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Stock Up 1.7 %

Shares of Alnylam Pharmaceuticals stock opened at $259.39 on Friday. The company's fifty day simple moving average is $248.21 and its two-hundred day simple moving average is $254.99. Alnylam Pharmaceuticals, Inc. has a 12-month low of $144.73 and a 12-month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market cap of $33.74 billion, a P/E ratio of -119.53 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the company earned ($0.16) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.